

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



石四藥集團有限公司

SSY Group Limited

(Incorporated in the Cayman Islands with limited liability)
(Stock Code: 2005)

QUOTATION OF JIANGSU BEST NEW MEDICAL ON THE NEEQ

References are made to the announcements of SSY Group Limited (the “**Company**”) dated 28 April 2022, 28 January 2022, 13 December 2021 and 18 October 2021 (the “**Announcements**”) in relation to the spin-off and separate quotation of the shares of Jiangsu Best New Medical Material Co., Ltd.* (江蘇博生醫用新材料股份有限公司) (“**Jiangsu Best New Medical**”) on the National Equities Exchange and Quotations (the “**NEEQ**”). Capitalised terms used herein shall have the same meaning as those defined in the Announcements, unless the context requires otherwise.

The Company is pleased to announce that the quotation of the shares of Jiangsu Best New Medical on the NEEQ will commence on 7 July 2022 under the stock code of 873710.

LISTING RULES IMPLICATIONS

As a part of the Possible Spin-off and the quotation of the shares of Jiangsu Best New Medical on the NEEQ, the Placing of 13,500,000 new shares of Jiangsu Best New Medical (representing approximately 6.32% of the enlarged issued share capital of Jiangsu Best New Medical) in the PRC has been completed, amongst which 11,400,000 shares were placed to third parties independent of and not connected with the Company and its connected persons at the total consideration of Renminbi (“**RMB**”) 23,370,000 (the “**Non-connected Placing**”) and 2,100,000 shares were placed to connected persons (as defined in the Listing Rules) of the Company at the total consideration of RMB4,305,000 (the “**Connected Placing**”). The Placing (comprising the Non-connected Placing and the Connected Placing) constitutes a deemed disposal by the Company of its interest in Jiangsu Best New Medical under Rule 14.29 of the Listing Rules.

As all the applicable percentage ratios calculated pursuant to Rule 14.07 of the Listing Rules in respect of the Placing are less than 5%, the Placing does not constitute a notifiable transaction under Chapter 14 of the Listing Rules and is not subject to the requirements under paragraph 3(e) of Practice Note 15 of the Listing Rules.

As all the applicable percentage ratios calculated pursuant to Rule 14.07 of the Listing Rules in respect of the Connected Placing are less than 0.1%, the Connected Placing is fully exempt from the requirements under Chapter 14A of the Listing Rules.

Shareholders of the Company and potential investors are reminded to exercise caution when dealing in the securities of the Company. Any person who is in doubt about his position or any action to be taken is recommended to consult his own professional adviser(s).

By order of the Board

Chow Hing Yeung

Executive Director and Company Secretary

Hong Kong, 6 July 2022

As at the date of this announcement, the Board comprises Mr. Qu Jiguang, Mr. Su Xuejun, Mr. Meng Guo and Mr. Chow Hing Yeung as executive Directors, Mr. Feng Hao as non-executive Director and Mr. Wang Yibing, Mr. Leung Chong Shun and Mr. Chow Kwok Wai as independent non-executive Directors.

* *for identification purpose only*